Which medications are undergoing drug trials to assess their efficacy in the treatment of IgA nephropathy?

Updated: May 19, 2020
  • Author: Sohail Abdul Salim, MD, FASN, FACP; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print

Trials of the following agents are in progress or completed:

  • Atacicept: Atacicept blocks the effects of BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), both of which are increased in IgA nephropathy and correlate with disease activity.
  • OMS721: OMS721 (narsoplimab) is a human monoclonal antibody that targets mannan-binding lectin-associated serine protease–2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. 
  • Sparsentan: This agent is a dual angiotensin II and endothelin-1 receptor antagonist

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!